Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
Wirnsberger, G.; Monteil, V.; Eaton, B.; Postnikova, E.; Murphy, M.; Braunsfeld, B.; Crozier, I.; Kricek, F.; Niederhoefer, J.; Schwarzboeck, A.; Breid, H.; Sanchez Jimenez, A.; Bugajska-Schretter, A.; Dohnal, A.; Ruf, C.; Gugenberger, R.; Hagelkrueys, A.; Montserrat, N.; Holbrook, M.; Oostenbrink, C.; Shoemaker, R. H.; Mirazimi, A.; Penninger, J. M.
Show abstract
The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is therefore paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by multiple VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- In silico, in vitro and in cellulo models for monitoring SARS-CoV-2 spike/human ACE2 complex, viral entry and cell fusion 96%
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity 95%
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies 95%
Similar papers in this journal
Similar papers in this journal
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 96%
- Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2 94%
- One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization 93%
Similar papers in this journal
- Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants 96%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 95%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.